Business
Bioasis Announces the Appointment of Christine Antalik as Chief Financial Officer
Bioasis Announces the Appointment of Christine Antalik as Chief Financial Officer.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n Bioasis \n Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or \n “Bioasis”), a pre-clinical, research-stage biopharmaceutical company \n developing its proprietary xB3 TM platform technology \n for the delivery of therapeutics across the blood-brain barrier (BBB) \n and the treatment of CNS disorders in areas of high unmet medical need, \n including brain cancers and neurodegenerative diseases, today announced \n the appointment of Christine Antalik as chief financial officer.\n \n \n “On behalf of our executive chairman Dr. Deborah Rathjen, our board of \n directors and our management team, it is my pleasure to welcome \n Christine to Bioasis. Christine has a proven track record in finance, \n including financing transactions, business development, strategic \n planning and guiding companies through significant growth. Her \n contributions will be critical as we work to strengthen the company’s \n market profile and continue to execute on our mission to advance our \n internal pipeline and license our proprietary xB3 platform \n technology,” said Mark Day, Ph.D., director, president and chief \n executive officer. “Christine’s integrity, people skills and strong work \n ethic have also demonstrated an excellent cultural fit with Bioasis, \n which will be key as she builds relationships with our board, management \n team and strategic partners, who share a strong belief in our ability to \n develop innovative medicines for the treatment of serious neurological \n diseases, including brain cancers.”\n \n \n Antalik has previously worked at a number of life sciences companies and \n brings diverse financial management experience in executing the \n strategic and financial plans of emerging companies with consistent \n successes in improving the performance and value of companies.\n \n \n “I am delighted to join Bioasis at a time when the company is preparing \n to reach major milestones in its development. I look forward to working \n in collaboration with Deborah, Mark and the management team to put in \n place a detailed financial roadmap and position the company for its next \n level of growth,” said Antalik. “I am excited by the potential of the \n Bioasis xB3 platform technology and admire the ...